Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines

Author： Giudice Stefania

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.4, 2012-08, pp. : 1484-1492

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Synthesis and biological evaluation of Fotemustine analogues on human melanoma cell lines

By Winum J.-Y. Bouissiere J.-L. Passagne I. Evrard A. Montero V. Cuq P. Montero J.-L.

European Journal of Medicinal Chemistry, Vol. 38, Iss. 3, 2003-03 ,pp. : 319-324

Elsevier

Access to resources Recommend Favorite

Thymidylate synthase inhibitors for non-small cell lung cancer

By Galvani Elena Peters Godefridus J Giovannetti Elisa

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1343-1356

Informa Healthcare

Access to resources Recommend Favorite

Linking Inflammation to Cell Cycle Progression

Current Pharmaceutical Design, Vol. 10, Iss. 14, 2004-05 ,pp. : 1653-1666

Bentham Science Publishers

Access to resources Recommend Favorite

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

By Li Tianhong

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 741-748

Springer Publishing Company

Access to resources Recommend Favorite

A Novel Treatment Approach for Extensive, Eruptive, Cutaneous Squamous Cell Carcinomas in a Patient Receiving BRAF Inhibitor Therapy for Metastatic Melanoma

By Fathi Ramin Kamalpour Loebat Gammon Bryan Tung Rebecca

Dermatologic Surgery, Vol. 39, Iss. 2, 2013-02 ,pp. : 341-344

Elsevier

Access to resources Recommend Favorite